The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...

NewLimit’s lead liver combo has proven its worth in preclinical models, Kimmel told Fierce, with the ability to boost ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

NewLimit, which plans to take its young-again cell reprogramming therapy into the clinic next year, raised a $435 million ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

NewLimit has come up with a new anti-aging breakthrough by developing a drug that can reverse the aging in human cells.

Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year ...

With "10 times the number of sets we had for season 1," the cast and crew discuss how they brought the Ba Sing Se chapter to ...